Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.

[1]  R. Zimmerman,et al.  Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. , 1991, Journal of neurosurgery.

[2]  H. Bloom,et al.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). , 1990, European journal of cancer.

[3]  W. Wara,et al.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. , 1990, Journal of neurosurgery.

[4]  G. Hofmann,et al.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. , 1989, Biochemistry.

[5]  P. Kleihues,et al.  O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. , 1989, Journal of neurosurgery.

[6]  J. Trojanowski,et al.  Phenotypic Analysis of Four Human Medulloblastoma Cell Lines and Transplantable Xenografts , 1989, Journal of neuropathology and experimental neurology.

[7]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[8]  L. Muhlbaier,et al.  Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. , 1988, Cancer Research.

[9]  D. Sullivan,et al.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. , 1987, The Journal of biological chemistry.

[10]  A. Wyllie,et al.  Apoptosis: Cell death in tissue regulation , 1987, The Journal of pathology.

[11]  E. Kosnik,et al.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Crooke,et al.  Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. , 1987, Molecular pharmacology.

[13]  P. Canal,et al.  Uptake and binding of teniposide (VM26) in Krebs II ascites cells. , 1987, Biochemical pharmacology.

[14]  W. Shapiro,et al.  In vitro drug sensitivity testing in human gliomas. , 1987, Journal of neurosurgery.

[15]  A. Bodley,et al.  Regulation of DNA topoisomerases during cellular differentiation. , 1987, NCI monographs : a publication of the National Cancer Institute.

[16]  A. Bricolo,et al.  Immunocytochemical characterization of long-term medulloblastoma cultures: preliminary report. , 1987, Progress in experimental tumor research.

[17]  Y. Pommier,et al.  Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. , 1986, Cancer research.

[18]  L. Liu,et al.  DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. , 1986, Cancer research.

[19]  W. Ross,et al.  Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. , 1986, Cancer research.

[20]  H. Bloom.  Treatment of Brain Gliomas in Children , 1986 .

[21]  P. Workman.  The Pharmacology of Brain Tumour Chemotherapy , 1986 .

[22]  J. Papadimitriou,et al.  Establishment of a Human Medulloblastoma Cell Line and Its Heterotransplantation into Nude Mice , 1985, Journal of neuropathology and experimental neurology.

[23]  W. Ross,et al.  Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. , 1985, Cancer research.

[24]  L. Liu,et al.  Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. , 1985, The Journal of biological chemistry.

[25]  C. Charnsangavej,et al.  New drugs and new delivery techniques. , 1985, Progress in experimental tumor research.

[26]  P. Smith,et al.  Limitations of the agar colony-forming assay for the assessment of paediatric tumours. , 1984, British Journal of Cancer.

[27]  B. Brownell,et al.  Monoclonal Antibodies as Reagents for Brain Tumour Diagnosis: A Review , 1984, Journal of the Royal Society of Medicine.

[28]  M. Muller,et al.  Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. , 1984, The EMBO journal.

[29]  J. Kemshead,et al.  The use of monoclonal antibodies for the diagnosis of intracranial malignancies and the small round cell tumours of childhood , 1983, The Journal of pathology.

[30]  P. Smith,et al.  Quantitation of chemosensitivity in acute myelocytic leukaemia. , 1983, British Journal of Cancer.

[31]  R. Benjamin,et al.  Clinical pharmacology of 2,5'-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ). , 1983, European journal of cancer & clinical oncology.

[32]  G. Barger,et al.  Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential. , 1983, Journal of neurosurgery.

[33]  L. Weisenthal,et al.  In vitro assays in preclinical antineoplastic drug screening. , 1981, Seminars in oncology.

[34]  Olufunmilayo I. Olopade,et al.  The Chromosomes in Human Cancer and Leukemia , 1981 .

[35]  K. Tveit,et al.  The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas , 1981, International journal of cancer.

[36]  L. Liu,et al.  A homogeneous type II DNA topoisomerase from HeLa cell nuclei. , 1981, The Journal of biological chemistry.

[37]  L. Liu,et al.  Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases. , 1981, Nucleic acids research.

[38]  S. Garattini,et al.  Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer. , 1981, Cancer treatment reports.

[39]  Barry H. Smith,et al.  Response of cultured human brain tumors to nitrosoureas: Correlation with clinical data , 1981, Cancer.

[40]  D. Alberts,et al.  Clinical correlations of in vitro drug sensitivity. , 1980, Progress in clinical and biological research.

[41]  D. Alberts,et al.  In vitro drug assay: pharmacologic considerations. , 1980, Progress in clinical and biological research.

[42]  L. Grochow,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[43]  P. Parsons,et al.  Cytotoxicity studies of human melanoma cells and fibroblasts. , 1979, The Australian journal of experimental biology and medical science.

[44]  T. F. Patton,et al.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man. , 1978, Cancer treatment reports.

[45]  V. Levin,et al.  Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. , 1978, Cancer treatment reports.

[46]  M. Root,et al.  Pharmacokinetics of vindesine and vincristine in humans. , 1977, Cancer research.

[47]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[48]  J. Draeger,et al.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. , 1976, Cancer treatment reports.

[49]  L. Mellett.  The Constancy of the Product of Concentration and Time , 1974 .

[50]  D. Ho,et al.  Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosine , 1971 .

[51]  J. D. Davidson,et al.  A method of analyzing for hydroxyurea in biological fluids. , 1963, Cancer chemotherapy reports.